A pharmaceutical composition for averting opioid addiction in a patient is disclosed. The composition can be used in a patient suffering from moderate to severe low back pain (LBP). The composition is useful in a patient diagnosed with low back pain, and comprises a therapeutically effective amount of an antibody that binds specifically to nerve growth factor (NGF) or an antigen binding fragment thereof; and is used in the absence of an opioid to relieve pain, and avert opioid addiction in a patient.